If Novo Nordisk is not a household name by now, you’ve surely encountered its flagship drugs. The Danish pharmaceutical giant has struck gold with its diabetes and obesity treatments, Ozempic, Rybelsus, and Wegovy. This triumvirate of remedies has catapulted Novo Nordisk stock an astonishing 72% in the last year. Current market capitalization makes Novo Nordisk the 14th most valuable company globally, outranking retail juggernaut Walmart, financial heavyweight Mastercard, and oil titan ExxonMobil. Following a red-hot fourth-quarter earnings reveal, Novo Nordisk stock is on a projected upward trajectory. Despite the lofty valuation, doubling down and snapping up shares now could prove to be a shrewd, long-term move.
Unveiling Novo Nordisk’s Magical Run
Novo Nordisk splits its revenue into four categories: rare diseases, insulin, obesity care, and glucagon-like peptide 1 (GLP-1) agonists. Encouragingly, the company experienced a surge of 154% and 52% in obesity care and GLP-1 products, respectively, in 2023. What’s more, its blockbuster drugs are not merely popular in the U.S. alone. Widely celebrated diabetes medication, Ozempic, and the breakthrough obesity solution, Wegovy, have contributed to the company’s 55% share of the GLP-1 market and robust international growth, with obesity care recording a 47% year-over-year surge. The company’s stellar performance has undeniably captivated global markets.
Image source: Getty Images.
Investor Sentiments and Stock Performance
Investors have not been stingy in rewarding Novo Nordisk. The stock rocketed 53% in 2023 and has continued its upward trajectory in 2024, increasing by 14% following what can only be described as a stellar earnings report. This extraordinary buying spree has propelled the company’s market capitalization to dizzying heights — a fact sharply depicted in the chart above, underscoring the marked shift in the company’s valuation over the past few years. In particular, 2023 was a standout year for the company, with its impressive results.
Buy Now, or Wait for What?
As investors, determining when to sell can be a challenge. Similarly, deciding when to buy a stock can be equally baffling. The soaring price of a stock can often dissuade investors, who fear being left holding the bag if the stock plummets. However, it’s important to remember that long-term investors tend to weather such pressures more adeptly. Novo Nordisk’s burgeoning footprint in the diabetes and obesity markets remains robust despite fierce competition, particularly from Eli Lilly. This competitive landscape can, in fact, be construed as a promising long-term catalyst. According to Barclays, the weight loss industry, hoodwinked by a market projection exceeding $200 billion by 2030, exhibits a decidedly optimistic outlook. Hence, evading the current premium and opting to buy shares later may actually not prove beneficial in the long haul. Thus, considering the prevailing positive sentiment in the long term, investing in Novo Nordisk now could be a fruitful endeavor.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.